Siegfried Reich
Nessuna posizione attualmente
Profilo
Siegfried Reich ha fondato eFFECTOR Therapeutics, Inc. Il dott. Reich è direttore scientifico e vicepresidente esecutivo di Turning Point Therapeutics, Inc. In passato ha ricoperto la posizione di vicepresidente presso Pfizer Inc. e di direttore e responsabile della chimica medicinale presso Agouron Pharmaceuticals LLC (una filiale di Pfizer Inc.), vicepresidente senior della ricerca presso eFFECTOR Therapeutics, Inc. e vicepresidente della ricerca di farmaci presso SGX Pharmaceuticals, Inc. Siegfried Reich ha conseguito una laurea presso la San Diego State University e un dottorato presso la University of California, Irvine.
Precedenti posizioni note di Siegfried Reich
| Società | Posizione | Fine |
|---|---|---|
| TURG POIN | Chief Tech/Sci/R&D Officer | 04/03/2022 |
SGX Pharmaceuticals, Inc.
 SGX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 18/04/2011 |
| PFIZER, INC. | Corporate Officer/Principal | 01/12/2005 |
Agouron Pharmaceuticals LLC
 Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | Director/Board Member | 01/01/2001 |
| EFFECTOR THERAPEUTICS, INC. | Founder | - |
Formazione di Siegfried Reich
| San Diego State University | Undergraduate Degree |
| University of California, Irvine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| EFFECTOR THERAPEUTICS, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
Agouron Pharmaceuticals LLC
Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | Health Technology |
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
SGX Pharmaceuticals, Inc.
SGX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA. | Health Technology |
eFFECTOR Therapeutics Operations, Inc.
 eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | Commercial Services |
- Borsa valori
- Insiders
- Siegfried Reich
